NPR1
Atrial natriuretic peptide receptor 1
As of the edition of 20 October 2026, NPR1 (atrial natriuretic peptide receptor 1, UniProt P16066) has 4 drugs tested at it and 4 companies on the list, 3 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P16066
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 14
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Lungs and airways; Inherited and neonatal; Nutrition and metabolism; Cancer; Immune system
- Registered trials of its drugs
- 51
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nesiritide | Marketed | Phase 4 | none listed |
| XXB750 | Stopped | Phase 2 | none listed |
| PL-3994 | Stopped | Phase 2 | none listed |
| Carperitide | Went quiet | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Novartis | Route A |
| Scios | Route B |
| Palatin Technologies | Route A |
The other 1 company at NPR1
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at NPR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.